Answers are grounded in this paper and cite their sources.
Evaluation of: Hung CF, Gibson SA, Letendre SL et al.: Impact of long-term treatment with neurotoxic dideoxynucleoside antiretrovirals: implications for clinical care in resource-limited settings. HIV Med. 9, 731–737 (2008). Dideoxynucleoside antiretroviral (d-drug) use is limited by peripheral nervous system toxicity. d-drugs are generically made and are cheaper antiretrovirals then branded non-d-drugs. In the context of financial barriers to delivering HIV care in resource-limited settings, cheaper d-drugs may mean the difference between treatment and no treatment. Whether or not d-drug neurotoxicity is cumulative could determine the applicability of d-drug use in resource-limited settings. In a US cohort of HIV-infected patients, the authors evaluated the safety of continued d-drug use by measuring the risk of d-drug to worsen neuropathy signs or symptoms. A total of 252 subjects on d-drugs were compared with 250 subjects on non-d-drug antiretrovirals and followed over a median of 18 months for signs of worsening neuropathy. The authors found continued d-drug use did not produce progressive signs or symptoms of neuropathy as compared with continued non-d-drug use, in agreement with the Delta trial and other recent cohort studies.
No takes yet. Share an insight, caveat, or question.
Elliott et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: